Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Get Free Report)'s share price gapped down before the market opened on Tuesday . The stock had previously closed at $39.71, but opened at $38.61. Ascentage Pharma Group International shares last traded at $39.10, with a volume of 501 shares trading hands.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. initiated coverage on shares of Ascentage Pharma Group International in a research report on Thursday, March 27th. They set an "overweight" rating for the company.
View Our Latest Stock Analysis on Ascentage Pharma Group International
Ascentage Pharma Group International Stock Performance
The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 3.24. The stock's 50-day moving average is $33.82.
Institutional Investors Weigh In On Ascentage Pharma Group International
A hedge fund recently bought a new stake in Ascentage Pharma Group International stock. Monashee Investment Management LLC acquired a new position in Ascentage Pharma Group International - Unsponsored ADR (NASDAQ:AAPG - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned about 0.18% of Ascentage Pharma Group International as of its most recent filing with the Securities and Exchange Commission.
About Ascentage Pharma Group International
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Featured Articles
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
